Last reviewed · How we verify
Increasing doses of GLP-1
At a glance
| Generic name | Increasing doses of GLP-1 |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Constipation
- Covid-19
- Vomiting
- Headache
- Decreased appetite
- Dyspepsia
- Gastrooesophageal reflux disease
- Abdominal pain
- Injection site reaction
- Upper respiratory tract infection
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (PHASE2)
- Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 (PHASE2)
- Semaglutide Treatment in Type 1 Diabetes (PHASE3)
- Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation (PHASE2, PHASE3)
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (PHASE3)
- HbA1c Variability in Type II Diabetes (NA)
- Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Increasing doses of GLP-1 CI brief — competitive landscape report
- Increasing doses of GLP-1 updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI